Literature DB >> 3091069

Autocatalytic quinone methide formation from mitomycin c.

D M Peterson, J Fisher.   

Abstract

Mitomycin c in the presence of NADPH and brewers' yeast NADPH: (acceptor) oxidoreductase (Old Yellow enzyme, EC 1.6.99.1) is transformed, at pH 8.0 and with anaerobicity, to two major mitosene products (the cis- and trans-1-hydroxy-2,7-diaminomitosenes; respective yields of 45 and 30%). These arise by covalent trapping by solvent of a quinone methide intermediate, obtained by rearrangement of the mitomycin c hydroquinone. At lower pH (6.5), the major product of this reaction is 2,7-diaminomitosene, which arises by covalent trapping of the quinone methide by H+. In the former instance the quinone methide acts as an electrophile and in the latter as a nucleophile. A detailed kinetic analysis indicates that the role of the NADPH and Old Yellow enzyme is to initiate an autocatalytic reaction, propagated by mitomycin c reduction by the mitosene hydroquinones (arising by the electrophilic pathway). The evidence supporting this conclusion is the formation of oxidized mitosene products, under the rigorously anaerobic reaction circumstance, the nonstoichiometric participation of NADPH, a dependence of the velocity on the total mitomycin c concentration, the pH dependence of the reaction, and the accurate simulation of the overall kinetic course with a mathematical model of the autocatalytic pathway. These observations indicate that the autocatalytic pathway may be dominant during in vitro mitomycin c anaerobic reductive activation by other reducing agents and that (as with anthracycline reductive activation) oxidation of the mitosene hydroquinone obtained from nucleophile addition to the quinone methide may be a necessary event for the formation of stable covalent adducts in vivo.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3091069     DOI: 10.1021/bi00362a014

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  9 in total

1.  Porfiromycin disposition in oxygen-modulated P388 cells.

Authors:  S S Pan
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Autoxidative and cyclooxygenase-2 catalyzed transformation of the dietary chemopreventive agent curcumin.

Authors:  Markus Griesser; Valentina Pistis; Takashi Suzuki; Noemi Tejera; Derek A Pratt; Claus Schneider
Journal:  J Biol Chem       Date:  2010-11-11       Impact factor: 5.157

Review 3.  Mitomycinoid alkaloids: mechanism of action, biosynthesis, total syntheses, and synthetic approaches.

Authors:  Phillip D Bass; Daniel A Gubler; Ted C Judd; Robert M Williams
Journal:  Chem Rev       Date:  2013-05-08       Impact factor: 60.622

4.  Cascade assembly of the benzo[a]anthraquinone ring system common to the angucycline antibiotics.

Authors:  Aleksandra Baranczak; Gary A Sulikowski
Journal:  Tetrahedron Lett       Date:  2012-03-14       Impact factor: 2.415

5.  Mitomycin C is not metabolized by but is an inhibitor of human kidney NAD(P)H: (quinone-acceptor)oxidoreductase.

Authors:  J J Schlager; G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

6.  Conversion of mitomycin C to 2,7-diaminomitosene and 10-decarbamoyl 2,7-diaminomitosene in tumour tissue in vivo.

Authors:  L Chirrey; J Cummings; G W Halbert; J F Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 7.  DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of mitomycin C.

Authors:  D Ross; D Siegel; H Beall; A S Prakash; R T Mulcahy; N W Gibson
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

8.  Modification of cellular DNA by synthetic aziridinomitosenes.

Authors:  Chris M Mallory; Ryan P Carfi; SangPhil Moon; Kenneth A Cornell; Don L Warner
Journal:  Bioorg Med Chem       Date:  2015-10-21       Impact factor: 3.641

9.  Characterization of a quinone reductase activity for the mitomycin C binding protein (MRD): Functional switching from a drug-activating enzyme to a drug-binding protein.

Authors:  M He; P J Sheldon; D H Sherman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-23       Impact factor: 11.205

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.